Drug intelligence / Profile preview

lepzacitinib

Development stage: Phase 2
Lead developer: Aclaris Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

Lepzacitinib is an investigational topical small molecule developed by Aclaris Therapeutics, which was originally acquired from Confluence Life Sciences. It functions as a Janus kinase (JAK) 1/3 inhibitor and is being developed for the treatment of moderate-to-severe atopic dermatitis. Aclaris Therapeutics has granted Pediatrix Therapeutics exclusive rights to develop, manufacture, and commercialize lepzacitinib in Greater China, while Aclaris retains rights for other territories and is actively seeking a global partner.

Other names: lepzacitinib

Targets

JAK3 (Janus kinase 3)JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on lepzacitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lepzacitinib.

Explore the full profile